Antibiotic prophylaxis in bariatric surgery with continuous infusion of cefazolin: Determination of concentration in adipose tissue

Obesity Surgery

Volumn 24, Issue 9, 2014, Pages 1487-1491

  Anlicoara, Rafael ^a   Ferraz, Álvaro A B ^a   Da P Coelho, Kilma ^a   De Lima Filho, José L ^a   Siqueira, Luciana T ^a   De Araújo Jr , José G C ^a   Campos, Josemberg M ^a   Ferraz, Edmundo M ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Antimicrobial prophylaxis; Bariatric surgery; Cefazolin; Obesity

Indexed keywords

CEFAZOLIN; ANTIINFECTIVE AGENT;

ADIPOSE TISSUE; ADULT; ANESTHESIA INDUCTION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BARIATRIC SURGERY; BODY MASS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG DOSE REGIMEN; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; STOMACH BYPASS; SURGICAL INFECTION; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OBESITY; PROCEDURES; SURGICAL WOUND INFECTION;

ADIPOSE TISSUE; ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BARIATRIC SURGERY; CEFAZOLIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OBESITY; SURGICAL WOUND INFECTION;

EID: 84906249516     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-014-1231-0     Document Type: Article

References (29)

1. World Health Organization. Obesity, situations and trends. http://www.who.int/gho/ncd/risk-factors/obesity-text/en/index.html.Accessed 25 July 2012.
2. Christou NV, Jarand J, Sylvestre JL, et al. Analysis of the incidence and risk factors for wound infections in open bariatric surgery. Obes Surg. 2004;14:16-22.
3. Alexander JW, Rahn R. Prevention of deep wound infection in morbidly obese patients by infusion of an antibiotic into the subcutaneous space at the time of wound closure. Obes Surg. 2004;14:970-4.
4. Freeman JT, Anderson DJ, Sexton DJ. Surgical site infections following bariatric surgery in community hospitals: a weight concern? Obes Surg. 2011;21(7):836-40.
5. Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg. 2001;234(3):279-89.
6. Chopra T, Zhao JJ, Alangaden G, et al. Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens. Expert Rev Pharmacoeconomics Outcome Res. 2010;10(3):317-28.
7. Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect. 2012;13(1):33-7.
8. Edmiston Jr CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery. 2004;136:738-47.
9. Liu P, Müller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentration. Int J Antimicrob Agents. 2002;19:285-90.
10. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007;27:1081-91.
11. Chen M, Nafziger AN, Drusano GL, et al. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother. 2006;50(4):1222-7.
12. Pai MP, Noremberg JP, Anderson T, et al. Influence ofmorbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007;51(8):2741-7.
13. Barbour A, Schmidt S, Rout WR, et al. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents. 2009;34:231-5.
14. Kees MG, Weber S, Kees F, et al. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother. 2011;66:2330-5.
15. Van Kralingen S, Taks M, Diepstraten J, et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011;67(10):985-92.
16. Cook AM, Martin C, Adams VR, et al. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother. 2011;55(7):3240-3.
17. Pevzner L, Swank M, Krepel C, et al. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol. 2011;117(4):877-82.
18. Rich BS, Keel R, Ho VP, et al. Cefepime dosing in the morbidly obese patient population. Obes Surg. 2012;22:465-71.
19. Anaya DA, Dellinger EP. The obese surgical patient: a susceptible host for infection. Surg Infect (Larchmt). 2006;7:473-80.
20. Ferraz AAB, Leão CS, Campos JM, et al. Profilaxia antimicrobiana na cirurgia bariátrica. Rev Col Bras Cir. 2007;34(2):73-7.
21. Signs SA, File TM, Tan JS. High-pressure liquid chromatographic method for analysis of cephalosporins. Antimicrob Agents Chemother. 1984;26(5):652-5.
22. Waltrip T, Lewis R, Young V, et al. A pilot study to determine the feasibility of continuous cefazolin infusion. Surg Infect. 2002;3(1):5-10.
23. Koopman E, Nix DE, Erstad BL, et al. End-of-procedure cefazolin concentrations after administration for prevention of surgical-site infection. Am J Health Syst Pharm. 2007;64:1927-34.
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. M100-S20. Vol 30, No. 1. Wayne (PA): Clinical Laboratory Standards Institute; 2010.
25. http://www.anvisa.gov.br/servicosaude/manuais/clsi.asp. Accessed 23 September 2012.
26. DiPiro JT, Edmiston CE, Bohnen JMA. Pharmacodynamics of antimicrobial therapy in surgery. Arch Surg. 1996;171:616-22.
27. Roberts JA, Paratz JD, Paratz E, et al. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007;30:11-8.
28. Roberts JA, Lipman J. Tissue distribution of beta-lactam antibiotics: continuous versus bolus dosing. J Pharm Pract Res. 2009;39:219-22.
29. Toma O, Suntrup P, Stefanescu A, et al. Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. Anesth Analg. 2011;113:730-7.